5-Amino-1MQ vs MOTS-c
5-Amino-1MQ and MOTS-c are both studied in metabolic research, but they couldn't be more different in origin — one is a small molecule found by knocking out a gene in mice, the other a peptide found hiding inside the mitochondrial genome.
At a Glance
| 5-Amino-1MQ | MOTS-c | |
|---|---|---|
| Category | Weight Loss & Metabolic | Weight Loss & Metabolic |
| Molecular class | Small molecule NNMT inhibitor — not a peptide | 16-amino-acid peptide encoded within mitochondrial DNA |
| Origin | 2014 genetic study (Kraus et al., Nature); compound introduced 2018 (Neelakantan et al.) | Discovered 2015, USC (Lee et al.) |
| Studied via | Oral administration | Subcutaneous injection |
| Primary mechanism | Inhibits NNMT, raising cellular NAD⁺/SAM levels | Activates AMPK / PGC-1α signaling |
| Primary research focus | Body weight, white adipose mass (mouse models) | Metabolic regulation, insulin sensitivity, exercise physiology |
| Human trial data | None — preclinical/animal only | None for MOTS-c itself; an analog was trialed, and a Phase 2a of MOTS-c itself is underway |
How They Differ
5-Amino-1MQ isn't a peptide at all, despite being sold alongside peptides in the same research category. Its research lineage starts with a 2014 genetic knockdown study that established NNMT (nicotinamide N-methyltransferase) as an obesity-relevant target in mice, followed by a 2018 pharmacology study that introduced 5-Amino-1MQ itself as a small-molecule inhibitor of that enzyme, reducing body weight and white adipose mass in diet-induced obese mice. See its full discovery history.
MOTS-c comes from an entirely different research tradition. Discovered in 2015 by researchers at USC, it's a genuine peptide — but one encoded within the mitochondrial genome itself rather than nuclear DNA, a class of molecule identified only within the last decade. It's studied for activating AMPK and PGC-1α, the same signaling pathway aerobic exercise triggers in muscle tissue. See its full discovery history, or how it compares to SS-31.
Clinical Trial Data
5-Amino-1MQ: All available data is preclinical. A 2014 genetic knockdown study (Kraus et al., Nature) established NNMT as an obesity-relevant target in mice, and a 2018 pharmacology study (Neelakantan et al., Biochemical Pharmacology, University of Texas Medical Branch) introduced 5-Amino-1MQ itself, showing it reduced body weight and white adipose mass in diet-induced obese mice without affecting food intake or lean mass. No human clinical trials have been conducted.
MOTS-c: MOTS-c itself has not completed a human clinical trial. CB4211, a novel analog of MOTS-c developed by CohBar (a related but distinct molecule, not MOTS-c itself), was tested in a Phase 1a/1b trial in 20 adults with obesity and elevated liver fat, meeting its primary safety endpoint with no serious adverse events and reducing the liver enzymes ALT (-25%) and AST (-17%) relative to placebo. Separately, a Phase 2a trial of MOTS-c itself ("MOTS-MET," NCT07505745) is currently underway, testing whether 12 weeks of subcutaneous MOTS-c improves insulin sensitivity in 120 adults with prediabetes and overweight or obesity; results have not yet been posted.
Why They're Often Studied Together
5-Amino-1MQ and MOTS-c are two of KYIN's three Weight Loss & Metabolic compounds, and together they illustrate two very different modern paths to finding a metabolic research target: classic small-molecule drug discovery, working backward from a gene-knockout finding to an enzyme inhibitor, versus endogenous peptide discovery, working forward from sequencing an overlooked genome (the mitochondrial one) to a naturally-occurring signaling molecule. Neither has completed human trials in its own right, making this a comparison of two early-stage research strategies rather than two products at different maturity levels.
5-Amino-1MQ vs MOTS-c questions
Why are 5-Amino-1MQ and MOTS-c often compared?
Because they're two of KYIN's three Weight Loss & Metabolic compounds and represent fundamentally different research approaches to metabolic health — small-molecule enzyme inhibition versus endogenous mitochondrial peptide signaling.
Is 5-Amino-1MQ actually a peptide?
No. Despite being sold alongside peptides in the same research category, 5-Amino-1MQ is a small molecule, not a peptide. It's studied as an inhibitor of the enzyme NNMT (nicotinamide N-methyltransferase), and unlike the injectable peptides in KYIN's catalogue, it's studied via oral administration in the available literature.
Does either 5-Amino-1MQ or MOTS-c have human clinical trial data?
No completed human trials exist for either compound itself. 5-Amino-1MQ's evidence is limited to mouse studies. MOTS-c itself has never completed a human trial, though a related but distinct analog (CB4211) was tested in a Phase 1a/1b trial, and a genuine Phase 2a trial of MOTS-c itself is currently underway.
Looking for specs and pricing?
View purity, available sizes, and pricing for both.